← Search & browse all drugs
DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Other dermatologicals
aminobenzoate potassium
D11AX23
Forms & Strengths
- Oral Powder: 2 g
- Oral Capsule: 500 mg
- Topical Gel/Ointment: 5% (Potaba)
Adult Dosing
- Peyronie's disease: 2 g oral 4 times daily with meals
- Fibrotic skin disorders: 2 g oral 4 times daily with meals
- Scleroderma: 2 g oral 4 times daily with meals
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Peyronie's disease
- Scleroderma
- Dermatomyositis
- Pemphigus
- Fibrosing conditions
Mechanism of Action
- Acts as a coenzyme in cellular oxygen consumption
- Decreases tissue monoamine oxidase activity
- Increases oxygen consumption in fibrotic lesions, potentially reducing fibrosis
Contraindications
- Hypersensitivity to aminobenzoate potassium or aminobenzoic acid
- Concurrent use with sulfonamides (antagonizes sulfonamide antibacterial activity)
Adverse Reactions
- Anorexia
- Nausea
- Vomiting
- Diarrhea
- Pruritus
- Rash
- Fever (hypersensitivity reaction)
Drug Interactions
- Sulfonamides: PABA antagonizes the antibacterial action of sulfonamides
- Potassium-sparing diuretics: May increase risk of hyperkalemia due to potassium content
Curated Content: Needs Vetting Before Put to Clinical Use